About P2Y purinoceptor 4
P2Y purinoceptor 4 (P2RY4) is a protein
from Homo sapiens identified by UniProt accession
P51582, 365 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | P2Y purinoceptor 4 |
|---|
| UniProt accession | P51582 |
|---|
| Gene | P2RY4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (38)
Diseases linked to this target (Open Targets).
- dry eye syndrome · score 0.55
- glioblastoma multiforme · score 0.24
- genetic disorder · score 0.12
- breast adenocarcinoma · score 0.10
- prostate adenocarcinoma · score 0.10
- acute kidney failure · score 0.07
- pyknoachondrogenesis · score 0.03
- Sepsis · score 0.02
- breast carcinoma · score 0.02
- cancer · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P51582-F1 | alphafold | PREDICTED | 82.58 | — |
Amino-acid sequence (365 residues)
MASTESSLLR SLGLSPGPGS SEVELDCWFD EDFKFILLPV SYAVVFVLGL GLNAPTLWLF IFRLRPWDAT ATYMFHLALS DTLYVLSLPT LIYYYAAHNH WPFGTEICKF VRFLFYWNLY CSVLFLTCIS VHRYLGICHP LRALRWGRPR LAGLLCLAVW LVVAGCLVPN LFFVTTSNKG TTVLCHDTTR PEEFDHYVHF SSAVMGLLFG VPCLVTLVCY GLMARRLYQP LPGSAQSSSR LRSLRTIAVV LTVFAVCFVP FHITRTIYYL ARLLEADCRV LNIVNVVYKV TRPLASANSC LDPVLYLLTG DKYRRQLRQL CGGGKPQPRT AASSLALVSL PEDSSCRWAA TPQDSSCSTP RADRL
Explore P2Y purinoceptor 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets